Loading...
Market
Will AstraZeneca face additional regulatory actions in China by mid-2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Official announcements from Chinese regulatory bodies or AstraZeneca
Story
AstraZeneca's China President and EVP Leon Wang Under Investigation; Shares Drop 3.5%
Oct 30, 2024, 02:00 PM
AstraZeneca announced at 9:00am that its China President and Executive Vice President of International, Leon Wang, is currently under investigation by Chinese authorities and is cooperating with the inquiry. The company's China operations will continue under the leadership of the current general manager. Following the announcement, AstraZeneca's shares dropped by 3.5%.
View original story
Similar markets
No charges filed • 25%
Fines imposed • 25%
Executives prosecuted • 25%
Other • 25%
Restructuring of Chinese operations • 25%
Increased compliance measures • 25%
Leadership changes • 25%
No significant changes • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Patent infringement lawsuit • 25%
Settlement agreement • 25%
Licensing agreement • 25%
No major legal action • 25%